Screening in Older People - When Not To
Existing guidelines recommend against screening for these tumours in individuals with limited life expectancy. Estimates put the cost to the U.S. healthcare system related to overdiagnosis at $1.2 billion annually.
The researchers assessed the prevalence of non-recommended screenings for breast and prostate cancers in the United States. Firas Abdollah, MD, of the Henry Ford Health System, Detroit, and colleagues analysed data from individuals who were 65 years or older and lived in the U.S. and who responded to the Behavioural Risk Factors Surveillance System survey in 2012.
See Also: ACS Guideline: Screening Mammography from 45
Of those 149,514 individuals — weighted to represent nearly 43.6 million people — there were 76,419 (51.1 percent) who had a mammography or prostate-specific antigen (PSA) test in the last year; 23,532 (30.8 percent) of those individuals had a life expectancy of less than 10 years. Those figures correspond to an overall rate of non-recommended screening of 15.7 percent (23,532 of 149,514 individuals), the researchers explain.
The results also showed that rates of non-recommended screening rates varied across the country, ranging from 11.6 percent in Colorado to 20.2 percent in Georgia. Interestingly, states with a high rate of non-recommended screening for breast cancer were likely to have a high rate of non-recommended screening for prostate cancer and vice versa.
Dr. Abdollah et al. note limitations to their study, including the possible overestimation of life expectancy and the inclusion of patients previously diagnosed, treated or observed for breast and prostate cancers.
“Efforts should be deployed to reduce non-recommended screening in states with a high rate of non-recommended screening. This effort may avoid significant harms to many individuals and improve the cost efficiency of screening initiatives,” the authors write.
Image credit: Flickr.com
Published on : Fri, 22 Jan 2016
Print as PDF
The TE7 touch screen ultrasound system is designed to provide superior quality imaging for rapid patient-care decisions. Intuitive gesture controls and efficient focused point-of-care exams minimize the user learning curve, with no need to navigate a...
Sectra's reporting module, developed with complex oncology cases in mind, facilitates overview of relevant priors together with the current request and report text. It also offers support for resident workflows and embedded links to images in the rep...
Sectra offers solutions for capturing, storing and accessing virtually all images, video, audio and documents. Sectra VNA allows you to consolidate image handling, while ensuring clinical workflow efficiency, growth management and business continuity...
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether imaging...
Sectra PACS is designed for a high production environment with stability and usability in focus. Highlights include functions to speed up oncology workflows such as anatomical linking and support for reviewing complex multiparametric MRI studies such...